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Dear Sirs,
Since the very beginning of the COVID-19 era, 
studies involving over 1000 patients revealed a high 
percentage of arterial hypertension history in infected 
patients. One of the first of those included 1099 pa-
tients with confirmed COVID-19, of whom 173 had 
severe disease with comorbidities of hypertension 
(23.7%), diabetes mellitus (16.2%), coronary heart 
diseases (5.8%), and cerebrovascular disease (2.3%). 
1 There is however no evidence that hypertension 
is related to outcomes of COVID-19. We, therefore, 
performed the meta-analysis of retrospective case 
series to estimate the outcome of COVID-19 patients 
with/without arterial hypertension history. Data from 
studies: Guan, et al. (2020) [1], Chen, et al. (2020) 
[2, 3], Wang, et al. (2020) [4], Zhou, et al. (2020) [5], 
Ruan, et al. (2020) [6], Du, et al. (2020) [7, 8] , Li, et 
al. (2020) [9], Zhang, et al. (2020) [10], Yuan, et al. 
(2020) [11], Wu, et al. (2020) [12] were included in 
the meta-analysis, as the only one is currently avail-
able after searching MEDLINE, Scopus and Web of 
Science databases up to April 15, 2020. The analysis 
was conducted following the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) 
statement. The meta-analysis showed that patients 
with preexisting arterial hypertension statistically sig-
nificantly more often have worse clinical outcomes 
when infected with SARS-CoV-2 (RR = 1.64; 95% CI, 
1.08–2.49; p = 0.02) (Fig. 1A). In addition, statistically 
significant differences were observed in the incidence 
of hypertension in the group of deceased versus cured 
(RR = 1.99; 95% CI, 1.63–2.41; p < 0.001) (Fig. 1B). 
This may confirm the hypothesis that arterial hyperten-
sion is one of the most important predictors affecting 
high morbidity and mortality of patients with COVID-19, 
although still the pathophysiological mechanisms are 
not fully understood.
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Yuan 2020 5 10 0 17 0.4% 18.00 [1.10, 294.88]
Zhou 2020 26 54 32 137 20.2% 2.06 [1.37, 3.11]
Total (95% CI) 310 595 100.0% 1.99 [1.63, 2.41]
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Study or Subgroup Events Total EventsTotal Weight
Risk Ratio 
M-H, Fixed, 95% CI
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Test for overall effect: Z= 4.81 (P < 0.00001)
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Figure 1. Forest plot of incidence of hypertension in COVID-19 patients; (A) being in severe versus no-severe condition; 
(B) decreased vs. cured. The center of each square represents the weighted risk ratio for individual trials, and the 
corresponding horizontal line stands for 95% confidence interval. The diamonds represent pooled results
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